Discover

BLCO
Bausch + Lomb Corporation
16.85
1 x 14.66
1 x 18.00
bid
ask
+
0.02
0.12%
1 @ 03:59 PM
16.87 +0.02 (0.12%)
Ytd-1.35%
1y23.62%
16.64
day range
17.02
13.61
52 week range
18.91
Open16.70Prev Close16.83Low16.64High17.02Mkt Cap6.02B
Vol156.49KAvg Vol434.41KEPS0.65P/E25.92Forward P/E15.38
Beta0.55Short Ratio9.93Inst. Own11.02%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2950-d Avg16.03200-d Avg16.381yr Est18.63
Earning
DateForEstimateReportedSurprisesurprise %
2026-11-042026-090.21N/AN/AN/A
2026-07-292026-060.150.160.013.63%
2026-04-292026-030.060.080.0233.33%
2026-02-182025-120.350.32-0.03-8.57%
2025-10-292025-090.160.180.0212.50%
2025-07-302025-060.060.070.0116.67%
Upgrade / Downgrade
DateFirmActionFromTo
2026-08-03HC Wainwright & Co.UpgradeBuyBuy
2026-07-30UBSUpgradeBuyBuy
2026-07-28UBSUpgradeBuy
2026-07-06Evercore ISI GroupUpgradeIn-LineIn-Line
2026-04-30Evercore ISI GroupUpgradeIn-LineIn-Line
2026-04-06Evercore ISI GroupUpgradeIn-LineIn-Line
Profile
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Insider Holder
DateNameRelationQuantityDescription
2026-03-05BAILEY AMBROSE ROBERT DOUGLAS J.D.Officer246.49KPurchase
2026-02-24BONNEFOY LUCOfficer117.94KStock Award(Grant)
2026-03-05ELDESSOUKY OSAMA AChief Financial Officer407.13KPurchase
2026-03-05ELDESSOUKY SAMChief Financial Officer407.13KPurchase
2026-08-04HASHAD YEHIAOfficer187.35KStock Award(Grant)
2026-08-04MUNSCH FREDERICK JOHNOfficer98.73KStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Icahn Carl C3.50M59.08M0.98%
2026-06-29Deutsche Bank AG3.42M57.78M0.96%
2026-03-30Oaktree Capital Management LP3.38M57.10M0.95%
2026-03-30Shaw D.E. & Co., Inc.3.15M53.19M0.88%
2026-03-30Goldentree Asset Management LP2.66M44.91M0.74%
2026-03-30Silver Point Capital L.p.2.25M37.90M0.63%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-05-30T. Rowe Price High Yield Fund, Inc.791.54K13.36M0.22%
2026-03-30-Price (T.Rowe) U.S. High Yield Trust273.62K4.62M0.08%
2026-05-30T. ROWE PRICE Inst. INCOME Fd.S, INC.-T. Rowe Price Inst. High Yield F210.03K3.55M0.06%
2026-03-30Unified Series Trust-BALLAST SMALL/MID CAP ETF149.93K2.53M0.04%
2026-06-29Gabelli Healthcare & WellnessRx Trust144.00K2.43M0.04%
2026-06-29Gabelli Dividend & Income Trust75.00K1.27M0.02%